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Abstract 
BACKGROUND: In this paper we discuss and present evidence on whether a generic 
Health Related Quality of Life (HRQoL) measurement tool, the EQ-5D-5L, captures the 
dimensions of quality of life (QoL) which patients consider significant. METHODS: An online 
survey, of individuals with a chronic condition, mainly breast cancer (BC), blood cancers 
(BLC), rheumatoid arthritis (RA), asthma, and rare diseases (RD) was conducted to collect 
data on HRQoL and important QoL aspects that respondents thought were not captured by 
the EQ-5D-5L. Patient organisations across 47 countries were invited to voluntarily share the 
survey tool with their membership network. RESULTS: 767 responses from 38 countries 
showed that important QoL aspects were not captured by EQ-5D-5L for 51% of respondents, 
including fatigue (19%) and medication side effects (12%), among others. Fatigue (17%) 
was also the most commonly reported QoL aspect that changed over the course of patients’ 
illness, suggesting that the current version of the EQ-5D-5L might miss capturing significant 
clinical changes in important QoL domains. CONCLUSIONS: Utilisation of the EQ-5D-5L in 
HRQoL measurement raises inconsistencies in capturing QoL attributes and changes in 
disease-specific patient populations.  Further research is needed to clarify the extent to 
which other generic HRQoL measurement tools capture the aspects of health that really 
matter for patients.  
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Highlights 
 
1. EQ-5D-5L didn’t capture key QoL dimensions for more than half of the sample.  
2. Several QoL aspects, notably fatigue, were identified as overlooked by EQ-5D-5L. 
3. Around 60% of patients reported changes on key QoL aspects during their illness. 
4. It is unknown if other generic HRQoL measurement tools face the same challenges. 
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Background  
Health Technology Assessment (HTA) is used extensively by health care systems globally, 
to inform resource allocation decisions around the uptake of new health technologies [1]. In 
order to be efficient, HTA must harmonize the interests of the general population, healthcare 
systems and individual patient groups. Essentially, HTA should recommend the uptake of 
cost-effective technologies, which have a substantial benefit to patients at an affordable cost, 
while balancing societal preferences [2]. Since patients are the end users of medical 
technologies it is imperative that their experiences play a significant role in HTA decision-
making. This is usually achieved through relevant data captured in clinical trials, which feed 
into HTA, while in certain cases, for example when in-depth understanding about the value 
and impact of a specific technology in patients’ lives is required, the inclusion of primary 
patient testimonies provides additional means for patient involvement in the HTA process [3, 
4], Despite a universal desire for a collaborative approach to healthcare decision-making, 
with patient involvement being an important priority, the input of patients, their caregivers 
and associated organizations towards HTA decision-making remains inadequate [4]. 
Evidence shows that only around half of the HTA bodies worldwide have reported the use of 
direct patient/caregiver involvement within any aspect of their processes [5]. Indirect patient 
involvement (e.g. through secondary evidence on patients’ Quality of Life (QoL)) is very 
often based on the use of evidence generated through generic Health Related Quality of Life 
(HRQoL) measurement tools, which have often been debated for their insufficiency in 
capturing key aspects of patients’ health status [3,6,7]. Health utilities can be measured 
indirectly using multidimensional, multi-attribute HRQoL questionnaires such as the Health 
Utilities Index 2 and 3 (HUI2 and HUI3), the Short Form 6D (SF-6D) and the EuroQol (EQ-
5D) [8].  Essentially, HRQoL data derived from patient populations help to generate Quality 
Adjusted Life Years (QALYs), a health utility metric which reflects health outcomes related to 
a treatment benefit and hence, serves as a baseline from which to tailor interventions, 
pharmacological or otherwise, and assess their comparative and cost effectiveness, both in 
the clinical trial setting and in routine care [17].  
Whilst these measures are all generic and not disease-specific, they differ considerably in 
terms of their content [9]. Even though EQ-5D and SF-6D are both being commonly used in 
economic evaluations [10], EQ-5D has become the most widespread generic measure of 
health utility used for economic evaluation in Europe [10] and internationally [11]. EQ-5D and 
its 5-level follow-on (EQ-5D-5L) have been certified in many countries worldwide [12, 13] 
and advocated for use in measuring the performance of a national health system [14], the 
real life effectiveness of interventions, and patients' preferences [15].   
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The EQ-5D-5L assesses areas of mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression, and identifies a total of 3125 (=55) possible health states, taking values 
from 0 (death) to 1 (perfect health) and therefore, presents with the fewest domains when 
compared to the other preference-based measures [8, 16].  
By imposing pre-defined domains on HRQoL measurement, this tool is also believed to lack 
dimensions of HRQL that may be impacted by chronic diseases (i.e. dexterity and social 
functioning); therefore, it raises questions as to the extent to which it represents the 
pragmatic QoL of individual patients or groups of patients [3, 8, 17]. Inevitably, unmeasured 
aspects with a potentially significant impact on an individual’s QoL encourage inaccuracies 
in HRQoL measurements and often result in diverse Health State Utility Values (HSUVs) 
being obtained by different instruments depending on the dimensions that each tool 
measures [10].  
An additional limitation of EQ-5D-5L is its limited responsiveness to clinical changes over the 
course of a treatment [3]. Health state improvement/deterioration, whether this arises as a 
consequence of treatment or of disease progression itself, should be reflected in the EQ-5D-
5L score in order to provide a reliable calculation of the QALYs gained/lost from a treatment. 
Since reimbursement decisions in many countries are primarily based on the cost/QALY 
metric, inaccurate QALY estimates could lead to resource allocation decisions that are not 
representative of the true benefit of an intervention.  
If coverage decisions are to reflect what matters to the users of a specific technology, their 
views should be embedded in the decision-making process and this could be achieved by 
capturing their perspective in a suitable utility measure. Given the widespread use of EQ-5D-
5L in HTA internationally, our study focused specifically on this tool, aiming to determine the 
perspective of individuals suffering from a variety of chronic conditions on how well the EQ-
5D-5L reflected their experience of illness.  
Methods  
Sample and Research design  
We conducted a web-based survey of an international patient population. Our sample 
comprised adult individuals diagnosed with at least one chronic condition. Participants were 
identified through a network of patients and patient associations’ representatives, held by the 
Medical Technology Research Group at the London School of Economics (LSE).   
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The survey was based on a multidimensional questionnaire comprising four sections, 
namely; a) patient demographic information and clinically relevant characteristics such as 
years since diagnosis and satisfaction with treatment received, b) HRQoL, measured with 
the EQ-5D-5L, so that patients could subsequently reflect on what was not covered by the 
tool c) respondents’ views about important QoL aspects that they felt EQ-5D-5L didn’t 
capture and d) aspects of illness that changed during the course of patients’ illness, as a 
proxy of to measuring the representativeness of EQ-5D-5L to clinical change.  
Questionnaires were made available in six languages and 320 patient associations across 
47 countries, primarily from Europe (308 - whether at national or supra-national level) were 
invited via e-mail to voluntarily share the questionnaire with their network of patients via e-
mail, blogs and social media accounts. The invitation to participate in the survey was sent to 
hundreds of patient organisations internationally, equally representing a variety of chronic 
disease patients, including Cancer (e.g. European Cancer Patient Coalition - ECPC), Breast 
Cancer - BC (e.g. EuropaDonna), Blood Cancer - BLC (i.e. Myeloma Patients Europe - 
MPE), Myelodysplastic Syndrome (MDS) (e.g. MDS-UK), Rheumatoid Arthritis - RA (e.g. 
European League Against Rheumatism - EULAR), Asthma (e.g. Asthma UK) and Rare 
Diseases - RD (e.g. Rare Connect), among others. A detailed list of the chronic diseases 
represented in this study is provided in the Appendix for clarification (Appendix, Table 1).  
In order to ensure anonymity, responses had no identification information.  All patients were 
informed about the study objectives and data confidentiality procedures in place and were 
asked to provide online written informed consent, to indicate their understanding of the study 
conditions and their agreement to participate. The study protocol was submitted to the LSE 
Research Ethics Committee and received an exemption.  
Preceding the actual survey questions, an online information sheet described the objectives 
of the survey, data confidentiality policies and provided individuals with a brief description of 
the EQ-5D-5L tool and its utilisation in HRQoL measurement. The survey was hosted online 
between June and August 2015 on Qualtrics® software under an LSE-verified account.  The 
IBM Statistical Package for Social Sciences (SPSS) version 21 was used to generate 
descriptive statistics (mean, median and standard deviation) and assess statistical 
significance of differences between groups.  
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Information and main variables of interest 
In order to gauge the extent to which EQ-5D adequately captures the aspects that impact on 
patients’ wellbeing the survey specifically asked patients to complete the EQ-5D-5L 
questionnaire and subsequently, to respond to the following questions i) “Are there any 
aspects of your illness, which have had a big impact on your health, that were not captured 
by the EQ-5D-5L” questionnaire which you completed previously – No/Yes, ii) “If yes, please 
tell us what they are”, iii) “Have the aspects of your illness, which have had a big impact on 
your health, changed over the course of your illness?” – No/Yes, iv) “If yes, please tell us 
what those changes were and how they have impacted your life”.  
Results  
Completion rate and sample size 
Based on the invitations to 320 patient associations, a total of 1,031 surveys were initiated 
from all 47 countries and 767 surveys were completed from 38 countries (completion rate of 
74%), namely Armenia (n=1), Australia (n=5), Austria (n=1), Belgium (n=9), Bulgaria (n=2), 
Canada (n=2), Croatia (n=12), Cyprus (n=32), Czech Republic (n=1), Denmark (n=37), 
Estonia (n=5), France (n=39), Germany (n=10), Gibraltar (n=1), Greece (n=55), Hungary 
(n=1), Ireland (n=7), Israel (n=2), Italy (n=6), Japan (n=1), Lithuania (n=2), F.Y.R.O.M (n=1), 
Malaysia (n=1), Malta (n=3), Moldova (n=1), Netherlands (n=33), Norway (n=3), Poland 
(n=3), Portugal (n=9), Romania (n=34), Serbia (n=4), Slovakia (n=4), Slovenia (n=15), Spain 
(n=10), Sweden (n=3), Switzerland (n=3), UK (n=400) and USA (n=9). 122 disease 
diagnoses were reported in total.  Cancer was the most common diagnosis (n=328, 48% of 
study sample), among which BC (n=180) and rare cancers (n=48) were dominant (23.5% 
and 6.2% of study sample respectively). Rare cancers mainly comprised blood cancer (BLC) 
diagnoses (n=31, 4% of study sample). Rare disease (RD) diagnoses (n=140, 18.2%), RA 
(n=53, 6.9%) and Asthma (n=24, 3.1%) were also represented (Appendix, Table 1).  
Sample demographic and HRQoL characteristics 
Average patient age was 50 (±14) years, the majority was females (77%), married/cohabiting 
(67%) and employed (40.7%). Average patient HSUV was 0.62 (±0.27), translating to an 
average utility loss of 28%, when compared to the general population in the study countries. 
Among the main disease groups of the study, the lowest average HSUV was reported by RD 
and RA patient groups (40% and 27% utility loss respectively), whereas the highest HSUV 
(i.e. 0.73, ±0.16) was observed for the BLC patient group.  
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Aspects not captured by EQ-5D-5L 
Our analysis showed that 51% (n=359) of all patients who responded (n=705) to the 
question; “which aspects of their illness had a big impact on their health, that were not 
captured by the EQ-5D-5L”, considered that the tool didn’t capture all the important 
wellbeing aspects that added a significant burden to their HRQoL (Figure 1). 
 
<Figure 1 about here> 
 
9.5% (n=34) of the above patients who reported that the tool didn’t capture all the important 
wellbeing aspects that added a significant burden to their HRQoL (n=359) did not provide a 
text response to describe the aspects of their illness that were not captured by the EQ-5D-
5L. By virtue of the free text responses available (n=325), it was highlighted that the most 
commonly reported wellbeing aspect not captured by the EQ-5D-5L was that of fatigue (19% 
of respondents who specified such aspects). Following were medication side effects (SEs) 
(12%) (i.e. “Tamoxifen caused depression and lack of libido”, “Hair loss”), presence of other 
co-morbid/long-term conditions (9.5%) (i.e. “While 'cured' of AML I have a compromised 
immune system and I am prone to chest infections. I have mild Graft-versus-host (GVH) 
disease affecting my eyes and acute arthritic attacks”), maintenance of relationships and 
social life (6.5%), issues with clinicians and social care received (6.2%), cognitive 
impairment (4.3%), sleep deprivation (4.3%), maintenance of family relationships (3.7%), 
worries/fear about the future (3.7%), work limitation (3.7%) and financial problems (2%) 
(Table 1).  
Other, less common aspects included; loss of confidence/self-esteem (1.9%) (i.e. “Self-
image, confidence”, “The view I have of myself”), sexual dysfunction (1.8%) (i.e. “Sexual 
discomfort”, “Vulvar fragility”), inability to exercise (1.5%), emotional distress (1.2%), inability 
to travel (<1%) and loss of senses; eyesight and hearing (<1%). Amongst the above, “loss of 
confidence/self-esteem” and “sexual dysfunction” were predominantly reported by BC 
patients (6% and 5% respectively). Finally, nearly 4% did not understand or had difficulty in 
understanding what the EQ-5D-5L tool was (i.e. “I have not done an EQ-5D-5L”, “I don't 
know what EQ-5D-5L is”).  
<Table 1 about here> 
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6.2% (n=20) of those who provided a free text response (n=325), primarily RD, BC and RA 
patients, reported that an important aspect of their wellbeing is related to issues experienced 
with the medical and social care received (Table 1); issues were raised that medical staff 
were not necessarily knowledgeable on providing the tailored care and treatment that RDs 
require, or that often, the way BC patients were informed about their diagnosis was felt to be 
appalling. Similarly, delayed diagnosis and access to treatment was an aspect that impacted 
greatly on the wellbeing of RA, diabetes and Multiple Sclerosis (MS) patients. In addition, 
5.2% of patients did not specify a health aspect that was not captured by EQ-5D-5L but 
instead, they provided comments highlighting the tool’s inability to capture daily variations of 
their wellbeing and QoL (Appendix, Table 3). Finally, 9.8% of individuals reported specific 
aspects of domains that were actually covered by the EQ-5D-5L, including 
anxiety/depression (4%), pain (3%) and mobility (1%), indicating that either they did not 
understand fully the items described by the EQ-5D-5L or that the EQ-5D-5L domains were of 
relevance to their wellbeing but they were not addressed adequately (i.e. did not fit the 
patients´ understanding of the individual items and their respective severity levels as 
phrased by the tool).  
Aspects that changed over the course of the disease 
57% (n=401) of all patients who responded (n=705) consider that the aspects of their illness 
that have a big impact on their health have changed over the course of their disease (Figure 
2).  
<Figure 2 about here> 
Excluding 7.7% (n = 31 out of 401) of respondents who did not provide a free text response 
on “what these changes were and how they had impacted their life”, for those who specified 
such changes (n=370), the most commonly reported were related to the following aspects; 
fatigue (17%), pain/discomfort (14%), mobility (12.4%), SEs (11.4%), treatment and/or 
healthcare received (n=26, 7%), work limitation (6.5%), usual activities (4.3%), maintenance 
of relationships and social life (3.8%), inability to exercise (3%), development of other co-
morbid/long-term conditions (3%), anxiety/depression (2.7%), and cognitive impairment 
(2.7%) (Table 2). Other less common aspects that changed included fear for relapse/ for 
future; (2.4%), sleep deprivation (2.1%), sexual dysfunction (1.3%), financial problems (1%), 
loss of confidence/self-esteem (1%), maintenance of family relationships (1%), 
appearance/bodily image (<1%), loss of senses; eyesight and hearing (<1%), and self-care 
(<1%). The aspect of “Fear for relapse” was primarily reported by cancer patients; i.e. 
“Anxiety for relapse” (BC patient),  “Ongoing worries about whether the cancer may come 
back,” (BC patient), “Worry of recurrence with each chest infection” (Lung cancer patient). 
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<Table 2 about here>  
Discussion 
We observed that EQ-5D-5L missed important health aspects in approximately 51% of an 
international, chronically ill population, although this percentage fluctuated according to 
disease area  
Overall, there were 17 additional QoL aspects identified, as being important but not 
represented by the EQ-5D-5L. In this context, the most commonly reported missing aspect 
(as reported by 19% of the entire sample and 24% of the cancer sample) was that of fatigue 
and loss of energy. A Swiss study [18] using a general adult population to elicit QoL 
preferences, reported on five additional, hypothetical EQ-5D-5L dimensions. Similarly to our 
results, the most frequent source of complaints was with regards to fatigue and lack of 
energy, although complaints regarding fatigue were higher (52.5% of complaints) in the 
Swiss study, in comparison to our study, possibly due to the smaller sample size used in the 
former.  
Comparably, a QoL survey on cancer patients showed that 43% of patients agreed or 
strongly agreed with the statement “I always feel tired” [19]. Fatigue has long been 
recognised as an important candidate for inclusion in the development of QoL valuation tools 
[20], as the role it plays in the worsening of the physical, mental, emotional and social 
aspects of QoL has been well documented [21-23]. It is associated with multidimensional 
consequences, ranging from functional impairment to interferences with employment, daily 
activities and relationships [23]. Specifically in cancer, fatigue has been linked to increased 
depression, anxiety, mood disturbances and negative impact on the family’s financial 
situation [24, 25]. Similarly, an explanatory study on EQ-5D bolt-on items (i.e. disease-
relevant items, supplementary to the EQ-5D-5L, for measuring HRQL in patient groups in 
which a generic measure has been shown to miss important dimensions) representing 
vision/hearing impairment and tiredness demonstrated that all bolt-ons significantly impacted 
on EQ-5D valuations, although the vision bolt-on appeared to be the most influential 
compared to hearing and fatigue [11]. Even though fatigue is clearly important to patients, its 
potential as a bolt-on item to the existing EQ-5D has been met with resistance [26]. 
Evidence has shown that when an experimental 6 domain version of the EuroQol 
questionnaire was tested in a pilot study, the impact that fatigue had on valuations was so 
small that it was deemed unnecessary to investigate further the development of a tool that 
adds fatigue as an additional domain [27].  Clearly, our findings are in direct contradiction 
with the above and this can be explained by using different target populations in each case.  
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Nevertheless, the issue of fatigue is complex.  It is the aspect of illness which many patients 
with chronic diseases report as having the highest impact on their daily living.  Fatigue can 
be related to both the disease and its treatment, and impacts a person’s wellbeing in ways 
that are different from their inability to carry out normal activities. A study of cancer patients 
found that fatigue affects more patients for more time than any other symptom and is 
regarded by patients as being more important than either pain or nausea/vomiting [28].  
Furthermore, we demonstrated that another potential shortcoming of EQ-5D-5L relates to its 
ability to capture changes in patient wellbeing over time. Evidence from the literature shows 
that there are issues with the use of the tool in situations where the natural history of the 
disease may vary, in the form of relapses and remissions, with specific evidence from 
conditions such as asthma, diabetes and MS [27]. Our findings are supportive of the 
literature, with nearly 6% of all patients across various conditions, including asthma, BC and 
RD questioning EQ-5D-5L’s ability to capture variations in patient wellbeing over time, which 
impacted on their QoL. Nevertheless, when interpreting these results it is important to keep 
in mind that measuring HRQoL consistently during periods of disease exacerbation may not 
be feasible, as such periods are usually short-lived.  
In addition, variations over time arising from a fear of relapse may have already been 
captured in other aspects of the tool [20], under domains such as anxiety.  However, our 
study findings did not support the above, as nearly 5% of those who specified important 
wellbeing changes (n=370), predominantly cancer patients, stated that anxiety and fear for 
the future, specifically related to the ‘threat’ of a relapse or a metastasis, were not captured 
by the EQ-5D-5L. In a similar context, we could infer that even though the issues 
experienced by 6.2% of respondents with medical and social care received could have 
indeed aggravated their anxiety and/or depression levels, their overall impact on patients’ 
QoL would have not necessarily been captured by the respective EQ-5D-5L domain of 
“anxiety/depression”. 
Additionally, our results showed that nearly 10% of individuals reported as “important 
aspects not captured by the EQ-5D-5L”, aspects that were actually covered by the 
instrument, although most likely not with the specificity, or at the severity level respondents 
expected. This discrepancy  raises the question of whether this was a result of the ‘framing’ 
of the health states and severity levels within the questionnaire [20] or a result of a 
misinterpretation of the domains and severity levels described. One can assume that indeed 
some EQ-5D items do not address patient-specific concerns adequately (i.e. they did not 
capture the level of severity that respondents expected).  
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Equally, it is possible that this may have been due to misinterpretation of the instrument 
descriptions leading to an over-estimation of those who thought EQ-5D didn’t capture 
important health aspects; in this case, it would likely also have more serious implications and 
should be examined further [35].  
 
Another aspect not captured by the EQ-5D-5L, mostly specific to cancer patients, included 
medication SEs. The weakness of the EQ-5D to capture problems arising due to adverse 
events has been documented elsewhere [27]. This is partly supported by our results, 
showing that 12% of those providing a free text response (n=325) felt that a domain relating 
to medication SEs was lacking. Specific concerns have been raised with respect to cancer 
treatment SEs as, very often the adverse reaction profiles of several therapies is 
characterized by fatigue/energy or nausea and as such, provides evidence for the 
importance of including the respective domains in an HRQoL measurement tool [27]. The 
above also relates to concerns that have been expressed elsewhere regarding the ability of 
the EQ-5D tool to pick up on subtle but important consequences of cancer, such as sexual 
dysfunction and confidence with self-image [3, 26, 29].  
In support of our findings, previous studies have demonstrated the potential that EQ-5D bolt-
on items have in enhancing the validity and responsiveness of the tool [7, 11, 30, 31]. 
However, as the impact of the bolt-ons depends on the severity of the bolt-on item and the 
severity of the state to which they are added, this raises questions as to whether future bolt-
ons need to be valued alongside the EQ-5D descriptions each time and as to the financial 
and practical challenges that come with increasing the number of health states included in a 
generic tool such as the EQ-5D-5L.  
Ultimately, we propose an alternative approach whereby a small subset of alternative health 
dimensions, specific to a particular subgroup of the population, are derived that could be 
used to sufficiently explain a large proportion of the variation in patient health utility. Different 
subsets of health dimensions could be employed depending on the disease at hand. The 
findings from this study demonstrate that an adaptive approach to EQ-5D-5L may be needed 
to capture disease-specific elements; alternatively, EQ-5D-5L could be used to add a 
generic element to a disease-specific tool thus capturing a significant part of unexplained 
heterogeneity that we observed in this study. A similar approach was used in one of the 
early studies in the field which included a generic bolt-on item with a condition-specific 
measure of HRQoL [31].    
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This discussion unavoidably links with the use of patient reported outcomes in drawing 
regulatory conclusions regarding treatment effects. Although there is debate around the use 
of such data in clinical trials [32, 33] and acceptance of their role in regulatory decision-
making [34], our study has shown that their usefulness stretches beyond estimates of patient 
perception of therapy side effects. The results of this study may, therefore, have important 
implications for a number of steps in data generation processes that lead to value 
assessments of new medical technologies in different settings: first, the kind of data that we 
ought to capture in clinical trials, second, how to reflect the broad patient population’s 
perspective and, third, what should regulatory bodies consider. Come what may, by 
confirming results from comparative efforts elsewhere, the present study showed that a more 
coordinated or broadly-based approach is needed and that leaving things as they are – the 
do-nothing option – does not appear to be acceptable to half the patient population 
surveyed.  
Study Limitations  
We believe that our analysis can prove valuable for improvements in future QoL research 
and HTA processes.  However, we acknowledge that certain methodological limitations have 
hindered the robustness of our findings. .  
The first limitation relates to sampling issues. Due to time constraints, a convenience  
sample was drawn, which mostly comprised European-based patients. As such, 71% of 
participating countries contributed less than 10 responses and the majority of responses 
were limited to BC, RA and RD patients. In obtaining the responses for this study, we relied 
on the voluntary involvement of patient organisations and since some of them have 
inherently generated greater participation in the survey, a greater sample size for the 
respective disease groups was achieved compared to others. Additionally, for logistic 
reasons the data collection was for a limited period only and this may have also impacted 
the number of organisations that responded and the diseases that are represented. 
Therefore, besides the sufficiently large overall sample size, our results might still not be 
representative of the true international population of chronically ill individuals.  
Furthermore, the use of a web-survey raises issues related to the interpretation of the survey 
questions by the respondents, the levels of understanding of the different EQ-5D-5L 
domains and the respective severity levels described. Therefore, the results presented in 
this paper should be interpreted with caution. Finally, the results presented here refer to EQ-
5D-5L only and as such cannot be generalised to other generic health state utility measures. 
Future research may employ a similar approach to assess the validity and/or responsiveness 
of other generic measures. 
 14 
Conclusion 
QoL is an important measure of disease burden, as unlike other measures, it takes into 
account patients’ subjective perceptions of wellbeing, treatment and overall QoL satisfaction. 
Understanding the factors which may reduce QoL outcomes is therefore important, for the 
implementation of more efficient disease management programmes, but also to pinpoint 
disease manifestations that may have previously been overlooked and accordingly, direct 
the development of new therapies.  It is therefore necessary to have appropriate tools in 
place to collect such data. However, due to practical issues, currently used HRQoL 
measurement tools typically focus only on a limited number of health dimensions and are 
thus believed to measure general health status rather than capturing QoL shaped by a 
unique combination of different important aspects for each individual.  
Despite its limitations, our study demonstrated that in a self-selected population, one of the 
most widely used QoL measurement tool, the EQ-5D-5L, indeed does not capture all 
aspects of health state that matter to patients. Inevitably, unmeasured health related aspects 
perceived to have a significant impact on an individual’s QoL generate inaccuracies in 
HRQoL measurements. Since reimbursement decisions in many countries are primarily 
based on the cost/QALY paradigm, utilization of inaccurate QALY estimates would imply that 
economic evaluations and consequently allocation decisions are not representative of the 
true benefit of an intervention.  
Consequently, the issues discussed in this study should guide further research, focused on 
clarifying the extent to which EQ-5D and other generic HRQoL measurement tools capture 
the aspects of health that really matter for patients, but more importantly, also the extent to 
which generic HRQoL measures, including the EQ-5D could be improved in order to capture 
such aspects.     
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Figure 1 
Proportion of patients across all sample and main disease areas reporting aspects not 
captured by the EQ-5D-5L 
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Figure 2 
Proportion of patients across all sample and main disease areas reporting that important 
QoL aspects changed over the course of their illness. 
 
 
 
Note: RD=rare diseases; BC=breast cancer; RA=rheumatoid arthritis; BLC=blood cancers. 
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Appendix 
Table1. All disease diagnoses reported by participants 
 
Cancer                                               (n=329)                    
Breast 180 
Myelodysplastic Syndrome (MDS) 55 
Blood  31 
Kidney 15 
Melanoma 9 
Cancer 9 
Brain tumor 2 
Medula Blastoma 2 
Glioblastoma Multiforme (GBM) 2 
Astrocytoma 1 
CRC 5 
Ovarian 4 
Oesophageal 3 
Prostate 3 
Thyroid 2 
Lung 2 
Appendix 2 
Angiosarcoma 1 
Duodenal 1 
Multiple cylindromas 1 
  
Arthritis                                            (n=100)                                      
Rheumatoid Arthritis 53 
Ankylosing Spondylitis 18 
Psoriatic A 14 
Arthritis 5 
Osteoarthritis 1 
Inflammatory 1 
Palindromic rheumatism 1 
Rare diseases                                                                   (n=140) 
A1-Antitrypsin deficiency 6 
Acute Intermittent Porphyria 1 
Adamantiades- Behcet syndrome 1 
Addison's disease 1 
Adrenomyeloneuropathy 3 
Alport Syndrome  1 
Ataxia (ADCA,SCA) 21 
Chronic granulomatous disease (CGD) 3 
Chronic infantile neurological cutaneous and articular (CINCA) 
syndrome 
1 
Churg-Strauss Syndrome 1 
Common Variable Immune Deficiency  (CVID) 2 
Complex regional pain syndrome 1 
Cryoglobulinemia  1 
Cystic Fibrosis 1 
Dercum’s Disease (Adiposis Dolorosa) 1 
Duchenne Muscular Dystrophy (DMD) 6 
Ehlers Danlos Syndrome (EDS) 40 
Erythromelalgia 1 
Familial Lipoprotein Lipase Deficiency 1 
Fibroydisplasia Ossoficans Progresiva 1 
Fragile X syndrome 1 
Gaucher disease 1 
Guillain–Barré syndrome (GBS) 3 
Hemophilia 1 
Hyper IgE Syndrome (Primary Immune Deficiency) 1 
Hypocomplementemic urticarial vasculitis syndrome (HUVS) 1 
Idiopathic Intracranial Hypertension  1 
Juvenile Idiopathic Arthritis 8 
Klippel-trenaunay syndrome 1 
Mal de Debarquement Syndrome 1 
Mitchondrial Neurogastroinestinal Encephalomyopathy (MNGIE) 1 
Mixed Connective Tissue Disease 1 
Myotonic Dystrophy  1 
Neuromyelitis Optica (NMO) 1 
Painful Bladder Syndrome 2 
Paroxysmal Nocturnal Haemaglobinuria 1 
Prader Willi Syndrome (PWS) 1 
Primary Antibody Deficiency  1 
Primary sclerosing cholangitis (PSC) 1 
Pudendal Neuralgia 1 
Pure Autonomic Failure 1 
Retinitis Pigmentosa (RP) 1 
SAPHO syndrome 1 
Stargardt disease 1 
Still syndrome 1 
Systemic sleroderma 5 
Tuberous sclerosis 2 
Wegener's Granulomatosis/Granulomatosis with polyangiitis 
(WG/GPA) 
3 
X-linked agammaglobulinemia (XLA) 1 
 24 
 
 
 
 
 
Other diseases                                                                             (n=198) 
Asthma 24 
Essential Tremor 23 
Systemic Lupus Erythematosus (SLE) 18 
Restless Leg Syndrome (RLS) 17 
Hypermobility Syndrome (HMS) 16 
Psoriasis 13 
HIV 9 
Multiple Sclerosis 8 
Gastroparesis (GP) 7 
Diabetes 6 
Stroke 6 
Parkinson's disease 5 
Hypertension 4 
Adrenal Deficiency Hyperactivity Disorder (ADHD) 3 
Chronic Obstructive Pulmonary Disorder (COPD) 3 
Fybromyalgia 3 
Sjogren's syndrome 4 
Crohn's disease 1 
Mediainfract ACI-occlusion 2 
Migraine 2 
Raynaud's syndrome 2 
Allergic Rhinitis 1 
Allergy 1 
Antiphospholipid syndrome  1 
Apoplexy 1 
Autosomal dominant polycystic kidney disease  (ADPKD) 1 
Borderline Personality Disorder 1 
Chronic Cystitis 1 
Chronic Fatigue Syndrome 1 
Cluster headaches 1 
Coeliac disease 1 
Depression 1 
Diffuse idiopathic skeletal hyperostosis (DISH)= Forestiers disease 2 
Dysautonomia 1 
Encephalomyelitis 1 
Genetic disease 1 
Haemorrhagic Ulcerative Collitis (RCUH) 1 
Hashimoto thyroiditis 1 
Kidney failure 1 
Lower back pain 1 
Lymphoedema 1 
Macular degeneration 1 
Myelofibrosis 1 
Oesteoprosis  1 
Persistent pelvic pain  1 
Pulmonary hypertension 1 
Sleep apnoea 1 
Thrombosis 1 
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Table 2 
Sample demographic and HRQoL characteristics 
 
Note: RD=rare diseases; BC=breast cancer; RA=rheumatoid arthritis; BLC=blood cancers.
 
All sample 
(n=767) 
BC 
(n=180) 
RD 
(n=140) 
RA 
(n=53) 
BLC 
(n=31) 
Asthma 
(n=24) 
Employment and demographics 
 
Age, mean (SD) 50 (14.13) 53 (9.3) 41 (14.4) 47 (11.2) 57 (12.6) 49 (17) 
Age at diagnosis, mean 
(SD) 
39 (17.5) 48 (9.8) 29 (17.3) 29 (14.4) 48 (13) 17 (16) 
Gender; Female, n (%) 592 (77%) 179 (99%) 111(79%) 46 (86%) 16 (51%) 19 (79%) 
Marital status, n (%) 
 
Single 
Married or cohabiting 
Divorced  
Separated 
Widow 
 
 
 
174 (22%) 
513(67%) 
50(6.5%) 
15(1.9%) 
15 (1.9%) 
 
 
21(11%) 
138 (76%) 
12 (6.6%) 
8 (4.4%) 
1 (0.5%) 
 
 
57 (40%) 
77 (55%) 
4 (2.8%) 
1(0.7%) 
1(0.7%) 
 
 
12 (22%) 
32 (60%) 
6 (11%) 
1 (1.9%) 
2 (3.8%) 
 
 
6 (19%) 
21(67%) 
2 (6.5%) 
0 
2 (6.5%) 
 
 
11 (46%) 
11 (46%) 
1 (4%) 
1 (4%) 
0 
Employment status, n (%) 
 
Employed 
Unemployed 
Temporary sick leave  
Permanent work disability 
Retired 
Housewife/husband 
Student 
Other (i.e. self-employed) 
 
 
 
312(40.7%) 
27 (3.5%) 
58(7.5%) 
19 (2.5%) 
83 (10.8%) 
182(23.7%) 
30 (3.9%) 
56 (7.3%) 
 
 
 
93 (51%) 
1 (0.5%) 
7 (3.9%) 
9 (5%) 
16 (8.9%) 
30 (16.6%) 
9 (5%) 
15 (8.3%) 
 
 
50 (3.5%) 
14 (10%) 
18 (12.8%) 
2 (1.4%) 
33 (2.3%) 
8 (5.7%) 
7 (5%) 
8 (5.7%) 
 
 
 
24 (45%) 
1 (1.9%) 
5 (9.4%) 
1 (1.9%) 
3 (5.6%) 
8 (15%) 
6 (11.3%) 
5 (9.4%) 
 
 
 
12 (38.7%) 
0 
1 (3.2%) 
2 (6.5%) 
0 
14 (45%) 
0 
2 (6.5%) 
 
 
 
10 (41%) 
1(4%) 
1(4%) 
0 
4 (16%) 
7 (29%) 
0 
1 (4%) 
 
HRQoL  characteristics 
EQ-5D-5L Utility, mean 
(SD) 
0.62(0.27) 0.7 (0.18) 0.46 (0.31) 0.58 (0.2) 0.73 (0.16) 0.74 (0.24) 
Utility loss, mean (SD) 0.24 (0.27) 0.15 (0.18) 0.4 (0.31) 0.27 (0.2) 0.12 (0.16) 0.12 (0.24) 
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